Larimar Therapeutics, Inc.
NASDAQ:LRMRBiotechnology
+$0.04 today
- Market cap
- $337.45M
- Beta
- 0.82
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.95
Volume 1.41M
Average 1.73M
LRMR Net Income
Bottom-line profit after all expenses, interest, and taxes.
Larimar Therapeutics, Inc.NASDAQ: LRMR
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$29.61M, compared with -$29.28M a year earlier. Trailing-twelve-month net income was -$166.01M.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$118.33M (+28.6%) for the fiscal year ending Dec 2026, a step up from the -105.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$29.61M+52.6% QoQ
- Last fiscal yearDec 2025
- -$165.67M-105.5% YoY
- LTMMar 2026
- -$166.01M-74.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -1.1% | -28.8% | -27.7 pp |
| 1 year | -105.5% | +28.6% | +134.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (165.67M) USD
- Year-over-year change
- -105.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (165.67M) | -105.5% |
| FY2024 | 2024-12-31 | (80.6M) | -118.1% |
| FY2023 | 2023-12-31 | (36.95M) | -4.5% |
| FY2022 | 2022-12-31 | (35.36M) | +30.2% |
| FY2021 | 2021-12-31 | (50.64M) | — |
Net Income vs competitors
How LRMR compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -74.3% is the lowest of 11, against a peer median of -12.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$33.61M USD | +61.8% | — | 15.6% | |
| LTM Mar 2026 | -CHF 66.22M CHF | -27.1% | — | 1788.8% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | -$66.4M USD | +16.9% | — | — |
| LTM Mar 2026 | -$74.31M USD | -17.6% | — | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$87.5M USD | +19.9% | — | — |
| LTM Mar 2026 | -$91.08M USD | -0.9% | — | 253002.8% | |
| LTM Mar 2026 | -$113.5M USD | -29.8% | — | 2954.1% | |
| LTM Mar 2026 | -$156.4M USD | -7.6% | — | — | |
| LTM Mar 2026 | -$166.01M USD | -74.3% | — | — | |
| LTM Mar 2026 | -$167.85M USD | -47.7% | — | — | |
| LTM Mar 2026 | -$196.48M USD | -17.4% | — | — | |
| Peer median (excluding LRMR) | — | -12.5% | — | 2371.5% | |
Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 38.4M | 24.25M | 27.67M | 73.28M | 154.22M |
| Selling, General & Admin | 12.07M | 12.28M | 14.09M | 17.61M | 18.27M |
| Operating Expenses | 50.47M | 36.53M | 41.76M | 90.89M | 172.5M |
| Depreciation & Amortization | 326K | 318K | 311K | 318K | 350K |
| EBITDA | (50.31M) | (35.04M) | (36.64M) | (80.29M) | (165.32M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (50.47M) | (36.53M) | (41.76M) | (90.89M) | (172.5M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (171K) | 1.17M | 4.81M | 10.29M | 6.82M |
| Income Before Tax | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| EPS (Diluted) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| Weighted Avg Shares | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
| Weighted Avg Shares (Diluted) | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
Larimar Therapeutics, Inc.
NASDAQ:LRMR
Intrinsic Alpha fair value
Locked
Current Price
$3.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.